Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
579.89
+6.74 (1.18%)
At close: Dec 3, 2025, 4:00 PM EST
579.00
-0.89 (-0.15%)
After-hours: Dec 3, 2025, 7:41 PM EST
Madrigal Pharmaceuticals Revenue
Madrigal Pharmaceuticals had revenue of $287.27M in the quarter ending September 30, 2025, with 362.03% growth. This brings the company's revenue in the last twelve months to $740.64M, up 864.21% year-over-year. In the year 2024, Madrigal Pharmaceuticals had annual revenue of $180.13M.
Revenue (ttm)
$740.64M
Revenue Growth
+864.21%
P/S Ratio
17.37
Revenue / Employee
$1,402,727
Employees
528
Market Cap
13.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 180.13M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MDGL News
- 13 days ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 16 days ago - Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences - GlobeNewsWire
- 23 days ago - Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis - GlobeNewsWire
- 4 weeks ago - Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 weeks ago - Biotech is back. Here's why these rallying stocks belong in your portfolio now. - Market Watch
- 5 weeks ago - Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025 - GlobeNewsWire